Role of the PP2A Pathway in Cholangiocarcinoma: State of the Art and Future Perspectives

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Nov 11

PMID 36358840

Authors

Ion Cristobal

Angela Lamarca

Affiliations

Soon will be listed here.

Abstract

Cholangiocarcinoma represents a heterogeneous disease at both a clinical and molecular level [...].

Citing Articles

Circular RNA Vav3 mediated ALV-J inhibition of autophagy by modulating the gga-miR-375/CIP2A axis and activating AKT.

Chen L, Xu H, Liu R, Yao Z, Xie Q, Zhang X Poult Sci. 2025; 104(4):104923.

PMID: 39987600 PMC: 11904538. DOI: 10.1016/j.psj.2025.104923.

Cholangiocarcinoma Malignant Traits Are Promoted by Schwann Cells through TGFβ Signaling in a Model of Perineural Invasion.

de Franchis V, Petrungaro S, Pizzichini E, Camerini S, Casella M, Somma F Cells. 2024; 13(5.

PMID: 38474330 PMC: 10930666. DOI: 10.3390/cells13050366.

A Novel Mouse Model of Combined Hepatocellular-Cholangiocarcinoma Induced by Diethylnitrosamine and Loss of .

Omella J, Cortesi E, Verbinnen I, Remmerie M, Wu H, Cubero F Cancers (Basel). 2023; 15(16).

PMID: 37627221 PMC: 10453342. DOI: 10.3390/cancers15164193.

References

Lu Z, Wang J, Zheng T, Liang Y, Yin D, Song R . FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling. BMC Cancer. 2014; 14:783. PMC: 4221672. DOI: 10.1186/1471-2407-14-783. View

Halder R, Amaraneni A, Shroff R . Cholangiocarcinoma: a review of the literature and future directions in therapy. Hepatobiliary Surg Nutr. 2022; 11(4):555-566. PMC: 9396092. DOI: 10.21037/hbsn-20-396. View

Cristobal I, Rincon R, Manso R, Madoz-Gurpide J, Carames C, Del Puerto-Nevado L . Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation. Biochim Biophys Acta. 2014; 1842(9):1823-9. DOI: 10.1016/j.bbadis.2014.06.032. View

Eichhorn P, Creyghton M, Bernards R . Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta. 2008; 1795(1):1-15. DOI: 10.1016/j.bbcan.2008.05.005. View

Westermarck J, Hahn W . Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med. 2008; 14(4):152-60. DOI: 10.1016/j.molmed.2008.02.001. View

Liu T, Fang Y, Zhang H, Deng M, Gao B, Niu N . HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy. Cancer Res. 2015; 76(3):572-81. PMC: 4737988. DOI: 10.1158/0008-5472.CAN-15-0671. View

Lamarca A, Edeline J, Goyal L . How I treat biliary tract cancer. ESMO Open. 2022; 7(1):100378. PMC: 8762076. DOI: 10.1016/j.esmoop.2021.100378. View

Xu P, Huang Q, Xie F, Xu X, Shao F . Increased expression of CIP2A in cholangiocarcinoma and correlation with poor prognosis. Hepatogastroenterology. 2013; 60(124):669-72. View

Zhou H, Xu J, Wang S, Peng J . Role of cantharidin in the activation of IKKα/IκBα/NF‑κB pathway by inhibiting PP2A activity in cholangiocarcinoma cell lines. Mol Med Rep. 2018; 17(6):7672-7682. PMC: 5983964. DOI: 10.3892/mmr.2018.8860. View

10.

Chen L, Guo P, Li W, Jiang X, Zhao Q, Li D . Protein phosphatase 2A regulates cytotoxicity and drug resistance by dephosphorylating AHR and MDR1. J Biol Chem. 2022; 298(5):101918. PMC: 9118923. DOI: 10.1016/j.jbc.2022.101918. View

11.

Mazhar S, Taylor S, Sangodkar J, Narla G . Targeting PP2A in cancer: Combination therapies. Biochim Biophys Acta Mol Cell Res. 2018; 1866(1):51-63. PMC: 6436821. DOI: 10.1016/j.bbamcr.2018.08.020. View

12.

Liu J, Yan G, Chen Q, Zeng Q, Wang X . Modified 5-aminolevulinic acid photodynamic therapy (M-PDT) inhibits cutaneous squamous cell carcinoma cell proliferation via targeting PP2A/PP5-mediated MAPK signaling pathway. Int J Biochem Cell Biol. 2021; 137:106036. DOI: 10.1016/j.biocel.2021.106036. View

13.

Xu P, Yao J, He J, Zhao L, Wang X, Li Z . CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine. Oncotarget. 2016; 7(12):14831-40. PMC: 4924755. DOI: 10.18632/oncotarget.7447. View

14.

Cristobal I, Manso R, Rincon R, Carames C, Senin C, Borrero A . PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential. Mol Cancer Ther. 2014; 13(4):938-47. DOI: 10.1158/1535-7163.MCT-13-0150. View

15.

Gouttia O, Zhao J, Li Y, Zwiener M, Wang L, Oakley G . The MASTL-ENSA-PP2A/B55 axis modulates cisplatin resistance in oral squamous cell carcinoma. Front Cell Dev Biol. 2022; 10:904719. PMC: 9554306. DOI: 10.3389/fcell.2022.904719. View

16.

Stafman L, Williams A, Marayati R, Aye J, Stewart J, Mroczek-Musulman E . PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells. PLoS One. 2019; 14(4):e0214469. PMC: 6457532. DOI: 10.1371/journal.pone.0214469. View

17.

Wang G, Dong J, Deng L . Overview of Cantharidin and its Analogues. Curr Med Chem. 2017; 25(17):2034-2044. DOI: 10.2174/0929867324666170414165253. View

18.

Seo S, Kim S, Shin J, Ham D, Shin E . GRA16 Inhibits NF-κB Activation through PP2A-B55 Upregulation in Non-Small-Cell Lung Carcinoma Cells. Int J Mol Sci. 2020; 21(18). PMC: 7554801. DOI: 10.3390/ijms21186642. View

19.

Liu H, Gu Y, Yin J, Zheng G, Wang C, Zhang Z . SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell. Cell Signal. 2014; 26(12):2710-20. DOI: 10.1016/j.cellsig.2014.08.010. View

20.

Hu M, Huang T, Chao T, Chen L, Chen Y, Tsai M . Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma. Liver Int. 2018; 38(12):2248-2259. DOI: 10.1111/liv.13887. View